We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.3B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 151 increasing their positions, 197 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

38% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 47

23% more capital invested

Capital invested by funds: $14B → $17.3B (+$3.3B)

3% more funds holding

Funds holding: 530544 (+14)

1.19% more ownership

Funds ownership: 16.09%17.28% (+1.2%)

23% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 197

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
544
Holders Change
+14
Holders Change %
+2.64%
% of All Funds
12.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
65
Increased
151
Reduced
197
Closed
47
Calls
$225M
Puts
$73.5M
Net Calls
+$152M
Net Calls Change
+$45M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
151
Prospector Partners
Connecticut
$2.37M
GC
152
Guggenheim Capital
Illinois
$2.36M +$23.1K +305 +1%
HighTower Advisors
153
HighTower Advisors
Illinois
$2.35M -$2.22M -29,335 -50%
CI
154
Capital International
California
$2.34M
ACM
155
Arlington Capital Management
Illinois
$2.32M -$289K -3,823 -12%
MML Investors Services
156
MML Investors Services
Massachusetts
$2.3M -$228K -3,014 -9%
EIM
157
Essex Investment Management
Massachusetts
$2.21M -$676K -8,933 -24%
RJT
158
Raymond James Trust
Florida
$2.16M -$384K -5,082 -16%
HCM
159
Huber Capital Management
California
$2.13M +$998K +13,200 +96%
Geode Capital Management
160
Geode Capital Management
Massachusetts
$2.09M +$81.2K +1,073 +4%
KeyBank National Association
161
KeyBank National Association
Ohio
$2.07M -$1.07M -14,192 -35%
MCM
162
McKinley Capital Management
Alaska
$2.07M +$1.11M +14,727 +129%
Baird Financial Group
163
Baird Financial Group
Wisconsin
$2.07M -$176K -2,327 -8%
DC
164
Diametric Capital
Massachusetts
$2M +$1.91M +25,213 New
Cambridge Investment Research Advisors
165
Cambridge Investment Research Advisors
Iowa
$1.94M +$30.3K +401 +2%
FA
166
FDx Advisors
Illinois
$1.9M -$1.26M -16,709 -41%
CWM
167
Cornerstone Wealth Management
Missouri
$1.87M +$281K +3,720 +13%
CBB
168
Citizens Business Bank
California
$1.83M -$45.4K -600 -3%
BG
169
Bollard Group
Massachusetts
$1.83M +$20K +264 +1%
TG
170
TCW Group
California
$1.8M +$252K +3,330 +17%
MYIA
171
Mount Yale Investment Advisors
Colorado
$1.75M -$401K -5,304 -19%
CA
172
Commerzbank Aktiengesellschaft
Germany
$1.73M
LNWWM
173
Laird Norton Wetherby Wealth Management
California
$1.68M +$303 +4 +0%
CIBC Asset Management
174
CIBC Asset Management
Ontario, Canada
$1.67M -$1.65M -21,818 -51%
FBT
175
First Bankers Trust
Kentucky
$1.67M -$132K -1,750 -8%

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.3B — up 23% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new AZN positions and 47 closed out — a net gain of 18 holders — while 151 added to existing stakes and 197 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 530 in Q2 2018.
  • Funds reported $17.3B of AstraZeneca stock for Q3 2018, up 23% quarter-over-quarter.
  • 65 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +18 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.